Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
life sciences
national blog main
boston
boston blog main
boston top stories
cancer
fda
national top stories
brexanalone
cancer immunotherapy
center for medicare and medicaid services
centers for medicare and medicaid services
clinical data
cms
cologuard
colon cancer
colorectal cancer
companion diagnostic
daniel o'day
deals
depression
dna
exact sciences
food and drug administration
foundation medicine
foundationone cdx
foundationone heme
genentech
healthcare
jeff jonas
major depressive disorder
medicare
mental illness
neuroscience
new york blog main
osimertinib
phase 3 trial
postpartum depression
psychiatric disorders
What
stock
3
×
acquire
adversity
agreed
approval
beats
big
billion
brexanalone
broad
cold
confidence
dealing
depression
didn’t
discussed
drug
early
exact
fda
flu
forecasts
foundation
gain
genentech
historically
hits
hour
industry
infusion
leaders
mark
medical
medicine
momentum
morning
obs
panels
pay
pays
Language
Current search:
stock
×
biotech
×
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
5 years ago
Exact Sciences Beats Quarterly Forecasts, Sending Its Stock Price Up
